#cardiac-arrhythmias #acquired-arrhythmias #gene-therapy #atrial-fibrillation #anticoagulation #stroke-prevention

Atrial Fibrillation (AF)

Definition

Atrial fibrillation is the most prevalent sustained cardiac arrhythmia, characterized by disorganized atrial electrical activity and elevated risk of thromboembolic events, heart failure, and all-cause mortality. It arises from a substrate of electrical and structural remodeling, focal ectopic activity, and re-entrant circuits.

Epidemiology

Global prevalence ~59.7 million in 2019; lifetime risk 1 in 3; expected to double by 2060. AF contributes to >250,000 deaths globally (2017 data); age-standardized mortality 4.0/100,000. (sources/AF-ESC-2024, rating: very high)
Adverse outcomes: 4–5× increased heart failure risk; 2.3× ischaemic stroke risk; 2× all-cause mortality; increased cognitive impairment (HR 1.39) and vascular dementia (HR 1.68). (sources/AF-ESC-2024)

Pathophysiology

Electrical remodeling: ↓ICa,L (L-type Ca²⁺ current), ↑IK1 (inward rectifier K⁺), ↑IKACh (constitutively active acetylcholine-gated K⁺) → shortened atrial APD → re-entry and arrhythmogenesis. (sources/gene-therapy-arrhythmia-2025, rating: high)
Detailed AF electrical remodeling: In persistent AF, IKACh (Kir3.1/Kir3.4, encoded by KCNJ3/KCNJ5) becomes constitutively active — no longer requiring acetylcholine binding — providing a background outward K⁺ current that mimics permanent vagal tone. ↓ICa,L shortens the AP plateau (Phase 2), resulting in a shortened, triangulated (loss of dome) atrial AP with reduced effective refractory period. ↓INa (Nav1.5 down-regulation) reduces conduction velocity → reentry wavelength shortens → multiple simultaneous wavefronts coexist → AF self-perpetuation. ↑IK1 deepens the resting membrane potential and increases rotor stability. Collectively these changes constitute AF-induced electrical remodeling, explaining the "AF begets AF" paradigm. (sources/membrane-potential-physrev-2021, rating: very high)
Pulmonary vein trigger ionic basis: PV sleeve myocardium retains fetal-type ion channel expression with greater If (HCN), ICa,T, and lower IK1. Under adrenergic stimulation, spontaneous diastolic depolarizations in PV myocytes (via NCX/Ca²⁺ sparks) generate ectopic triggered beats that initiate AF episodes in the genetically susceptible atrial substrate. (sources/membrane-potential-physrev-2021)
Structural remodeling: Atrial fibrosis (TGF-β-mediated) → conduction heterogeneity → AF maintenance. (sources/gene-therapy-arrhythmia-2025)
Conventional therapies (antiarrhythmic drugs, catheter ablation) have suboptimal long-term efficacy; adverse effect profiles limit long-term use. (sources/gene-therapy-arrhythmia-2025)

Risk Factors

Obesity

Obesity accounts for ~1/5 of AF cases and 60% of recently documented population increases in AF prevalence. (sources/obesity-cv-aha-2021, rating: very high)
Every 5-unit BMI increment confers a 29% greater risk of incident AF; each 5-unit increment also confers a 10% increase in postoperative AF and a 13% increase in post-ablation AF. (sources/obesity-cv-aha-2021, rating: very high)
AF progression with obesity: BMI 30–34.9 → 54% increased likelihood of progression from paroxysmal to permanent AF; class 2 obesity (BMI 35–39.9) → 87% increased risk. (sources/obesity-cv-aha-2021, rating: very high)
SDB-AF association (HR 2.18) exceeds obesity-AF association (HR 1.49) — SDB is a stronger AF driver than obesity alone; see concepts/OSA-Arrhythmogenic-Substrate. (sources/sdb-arrhythmia-aha-2022, rating: very high)
Epicardial adipose tissue (EAT) as AF substrate: EAT infiltrates atrial myocardium adjacent to fat depots → voltage abnormalities, conduction block, AF vulnerability. The EAT–AF association is stronger than overall or abdominal obesity–AF association. Three arrhythmogenic pathways: (1) structural — adipose infiltration creates "zigzag" conduction barriers → fractionated electrograms → re-entry; fibro-fatty replacement more extensive in persistent than paroxysmal AF; (2) electrotonic coupling — hypothetical Cx43-mediated coupling between EAT adipocytes and cardiomyocytes → RMP depolarisation → altered excitability/conduction (unproven in humans); (3) paracrine secretome — TNF-α/IL-1β reduce Ito → APD prolongation; IL-6 downregulates Cx40/Cx43; TGF-β1/activin A/leptin/MCP-1 drive fibrosis; EVs from AF patients' epicardial fat contain profibrotic miRNA and induce rotors in hiPSC-CMs. ECG correlates: prolonged P-wave/PR (10–16 ms), fragmented QRS, elevated Tpeak–Tend. See concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high; sources/obesity-cv-aha-2021, rating: very high)
Weight loss and AF — the 4th pillar of AF management: A RCT (n=150) of intensive weight loss + cardiometabolic risk factor management → greater reduction in cumulative AF time, symptom burden, and severity scores (+ cardiac remodeling) at 15 months. Cohort study: ~5-fold higher freedom from AF after ablation in patients attending intensive risk factor clinic vs. controls. Long-term follow-up (5 years): achieving ≥10% weight loss → ~6-fold higher freedom from AF and reduced AF disease progression. Weight management is now recognized as a 4th pillar of AF management alongside rate/rhythm control, stroke prevention, and comorbidity management. (sources/obesity-cv-aha-2021, rating: very high)
See entities/Obesity, concepts/Visceral-Adiposity, and concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis for mechanisms.

Sleep-Disordered Breathing and Obstructive Sleep Apnea

SDB (OSA + CSA) is present in 21–74% of AF patients (vs. 3–49% general population); most AF+OSA patients do not report daytime sleepiness — symptom-based screening is unreliable. (sources/sdb-arrhythmia-aha-2022, rating: very high; sources/osa-af-jama-2018, rating: high)
Nearly 5-fold higher odds of AF with moderate-to-severe SDB after adjusting for obesity and cardiovascular risk. (sources/sdb-arrhythmia-aha-2022)
Arrhythmogenic substrate: OSA creates a unique complex and dynamic substrate through dual mechanisms: acute apnea-associated electrophysiological changes (atrial stretch, shortened refractoriness, sympathovagal activation → premature atrial contractions) and long-term structural remodeling (atrial fibrosis, connexin dysregulation, conduction slowing). See concepts/OSA-Arrhythmogenic-Substrate. (sources/osa-af-jama-2018)
VARIOSA-AF: Nights with highest SDB severity had 2× the likelihood of ≥1 hour of AF the following day vs. lowest SDB severity; AF episodes did not predict respiratory events — SDB → AF directionality established. (sources/sdb-arrhythmia-aha-2022)
SDB-AF magnitude of association (HR 2.18) exceeds obesity-AF (HR 1.49) — SDB may be a stronger AF driver than obesity. (sources/sdb-arrhythmia-aha-2022)
Nocturnal hypoxia (not AHI) predicted incident AF independently (HR 2.47 [95% CI 1.64–3.71]) in 8,256 patients. AHI may be an inferior metric vs. nocturnal hypoxemic burden for predicting AF risk. (sources/sdb-arrhythmia-aha-2022)
CSA associated with 5.3–6.5 year excess AF risk (OR 3.00 CSA; OR 2.58 central apnea; OR 2.27 CSB). (sources/sdb-arrhythmia-aha-2022)
Other sleep disturbances: frequent nocturnal awakenings (33% ↑ risk), insomnia (36% ↑ risk), short slow wave sleep — all independently associated with AF. (sources/sdb-arrhythmia-aha-2022)
Impact on AF treatment efficacy: OSA reduces efficacy of all AF treatments — antiarrhythmic drugs (lower response rate in severe OSA), cardioversion (82% recurrence at 12 months without CPAP vs. 53% in non-OSA vs. 42% with CPAP), and catheter ablation (31% greater recurrence after PVI; HR 8.81 for PVI failure with untreated OSA + non-PV triggers). (sources/osa-af-jama-2018)
CPAP: Observationally restores AF recurrence rates to near those of non-OSA patients after cardioversion and PVI (no AF-specific RCT evidence as of 2018); benefits strongest in younger, obese, and male patients. (sources/osa-af-jama-2018)
Screening: Sleep study evaluation is reasonable in AF patients being considered for rhythm control strategy regardless of sleepiness symptoms. Polygraphy is a practical screening modality. AHA 2022 consensus: screen for OSA in AF (obesity, HT, nocturnal AF predominance); treat SDB as part of lifestyle modification; CPAP supported by observational data but not confirmed by RCTs (SAVE, Caples, Traaen). (sources/osa-af-jama-2018; sources/sdb-arrhythmia-aha-2022)
Guidelines: AHA 2023 — sleep apnoea treatment listed under LRFM (Class I). ESC 2016 — OSA interrogation and CPAP to reduce AF recurrence (Class IIa, Level B). (sources/AF-AHA-2023; sources/osa-af-jama-2018)
See entities/Obstructive-Sleep-Apnea for full detail.

MASLD and Metabolic Syndrome

MASLD is associated with ×1.2–1.5 increased long-term risk of atrial fibrillation (updated meta-analysis, Liver Int 2025), sharing metabolic substrate with obesity-related AF (visceral adiposity, insulin resistance, systemic inflammation). (sources/masld-nejm-2025, rating: high)
The magnitude of MASLD-AF association (×1.2–1.5) is lower than SDB-AF (HR 2.18) and obesity-AF (HR 1.49 per 5-unit BMI increment), suggesting MASLD is a modifiable AF risk marker — particularly relevant in patients presenting with unexplained AF and metabolic syndrome features. (sources/masld-nejm-2025, rating: high)
Mechanistic pathway: MASLD-driven insulin resistance and visceral adiposity → epicardial adipose tissue expansion → atrial structural and electrical remodeling → AF substrate. MASLD also increases new-onset HF risk ×1.2–1.5 and new-onset T2DM ×2.2, which are themselves independent AF risk factors. (sources/masld-nejm-2025, rating: high)
See entities/MASLD for full MASLD epidemiology, CV risk, and pharmacotherapy. GLP-1 receptor agonists (semaglutide, tirzepatide) and SGLT2 inhibitors used for MASLD also reduce AF risk via weight loss and metabolic improvement — see entities/Semaglutide and entities/HFpEF.

Hypertension

Hypertension has the highest attributable risk for AF development of any modifiable risk factor; present in >80% of AF patients and the most common comorbidity regardless of age. (sources/HT-AHA-2025, rating: very high)
Both AF and hypertension increase in frequency with age; uncontrolled hypertension is a key component of multiple AF and CVD risk prediction scores. (sources/HT-AHA-2025)
BP control reduces incident AF, especially in patients with HF; in patients with established AF, optimal BP control reduces MACE including stroke. (sources/HT-AHA-2025)
BP goal in AF: <130/80 mmHg — general hypertension guidelines apply; no dedicated RCT establishes an AF-specific BP target. (sources/HT-AHA-2025)
ACEi/ARB for AF prevention: Small studies and meta-analyses suggest reduction in recurrent AF; more definitive evidence is needed. MRAs reduce AF burden in small studies and secondary analyses of RCTs. (sources/HT-AHA-2025)
Lifestyle modifications that result in lower BP (weight loss, exercise, sodium reduction, alcohol reduction) may decrease AF recurrence — convergent pathways with standard AF risk factor management. (sources/HT-AHA-2025)
See entities/Hypertension for full BP management framework, treatment thresholds, and medication guidance.

Drug-Induced Atrial Fibrillation

A broad range of medications can cause or exacerbate AF/AFL; this is an underappreciated clinical cause of new-onset AF. (sources/drug-arrhythmia-aha-2020, rating: very high)
Anticancer agents are a major category: tyrosine kinase inhibitors (cetuximab, sunitinib, sorafenib; ibrutinib 3.3–6.5% — highest risk); anthracyclines (doxorubicin 1.4–13.8%); HER2/Neu receptor blockers (trastuzumab 1.2–19.9%); alkylating agents (cisplatin, cyclophosphamide, up to 15.5%); mechanisms include reactive oxygen species, inflammation, ion channel dysfunction, and thyrotoxicosis (kinase inhibitors). (sources/drug-arrhythmia-aha-2020)
Antipsychotics: chlorpromazine (OR 1.96), clozapine (OR 2.81), quetiapine (OR 1.55), olanzapine (OR 1.81), risperidone (OR 1.25) — via altered autonomic tone and muscarinic blockade causing atrial conduction abnormalities. (sources/drug-arrhythmia-aha-2020)
Catecholaminergic agents: dobutamine (0–18%), dopamine, epinephrine — via β-adrenergic stimulation, shortened atrial ERP, and increased pulmonary vein ectopy. (sources/drug-arrhythmia-aha-2020)
Alcohol: pooled OR/RR 1.51; dose-dependent; mechanisms include shortened atrial ERP, increased sympathetic and vagal activity, and interatrial electromechanical delay. (sources/drug-arrhythmia-aha-2020). Note: Mendelian randomization studies negate the prior observational protective association of low/moderate alcohol with coronary artery disease; alcohol and BP have a linear relationship from the lowest intake levels — 2025 AHA/ACC HT guideline recommends avoiding alcohol for hypertension prevention. (sources/diet-aha-2026, rating: very high)
Fish oil supplements (omega-3 fatty acids): Fish oil supplementation has not been demonstrated to lower CVD risk in otherwise healthy adults and may be associated with increased AF risk; dietary fish (non-fried seafood) does not carry this risk signal. Icosapent ethyl (prescription-grade concentrated EPA, 4 g/day) similarly carries an AF risk signal (~1% absolute increase vs. placebo). (sources/diet-aha-2026, rating: very high)
Bronchodilators (β-agonists, theophylline): β₂-adrenergic and phosphodiesterase-mediated mechanisms; avoid excessive stimulant use and maintain theophylline <20 μg/mL. (sources/drug-arrhythmia-aha-2020)
Class IC antiarrhythmics (flecainide, propafenone): Can convert AF to AFL with 1:1 AV conduction and wide QRS — AV nodal blocking drug must always be co-prescribed in patients with AFL taking these agents. (sources/drug-arrhythmia-aha-2020)
NSAIDs/COX-2 inhibitors: Modest but statistically significant AF risk (diclofenac IR 1.2–1.4; etoricoxib HR 1.35) — mechanism involves reduced endogenous antiarrhythmic prostacyclin via COX-2 inhibition. (sources/drug-arrhythmia-aha-2020)
Management: Discontinue offending agent (many self-convert to sinus rhythm); rate control with AV nodal blocking agents; TOE or ≥3 weeks therapeutic anticoagulation before cardioversion if AF ≥48 h or unknown duration; hemodynamically unstable → urgent cardioversion. (sources/drug-arrhythmia-aha-2020)
See concepts/Drug-Induced-Arrhythmia for full drug catalog by arrhythmia type.

Diagnosis and Screening

ECG confirmation required (12-lead, single- or multi-lead) with ≥30 s recording; physician review required. PPG/smartwatch alone is not diagnostic (Class I/A). (sources/AF-ESC-2024, rating: very high)
Opportunistic screening: Pulse-taking or ECG rhythm strip at every clinical visit is recommended during BTK inhibitor therapy (Class I/C); screen for OSA in all AF patients being considered for rhythm control strategy regardless of symptoms. (sources/Cardio-Oncology-ESC-2022; sources/osa-af-jama-2018)
Wearables/CIEDs: Device-detected subclinical AF (SCAF/AHREs) requires electrogram review — false-positive AHRE rate ~17% (ASSERT). SCAF detected in 10–50% of CIED populations; carries 2.4× stroke risk. See concepts/Subclinical-AF for full detail. (sources/subclinical-af-aha-2019, rating: high)

Clinical Staging

AHA 4-Stage Classification (2023): Stage 1 (At Risk) → Stage 2 (Pre-AF) → Stage 3 (AF: 3a paroxysmal, 3b persistent, 3c long-standing, 3d post-ablation sinus rhythm) → Stage 4 (Permanent). Replaces duration-based classification. (sources/AF-AHA-2023, rating: very high)

Management

Comorbidity and Risk Factor Modification

AF-CARE framework (ESC 2024): [C] Comorbidity management → [A] Avoid stroke → [R] Rate/rhythm control → [E] Evaluation. Comorbidity management is the first and foundational pillar. (sources/AF-ESC-2024, rating: very high)
LRFM (AHA 2023): Smoking cessation (Class I/B-NR), weight loss ≥10% (Class I/B-R; also Class I/B ESC 2024 — upgraded from IIa), 210 min/week moderate exercise, alcohol reduction, sleep apnoea treatment; caffeine restriction not recommended (Class III: No Benefit). (sources/AF-AHA-2023, rating: very high)
SGLT2 inhibitors: Class I/A for AF patients with HF regardless of ejection fraction. (sources/AF-ESC-2024)
For detailed risk factor data (obesity, SDB/OSA, MASLD, hypertension, drug-induced AF), see Risk Factors section above.

Stroke Prevention / Anticoagulation

Thromboembolic risk scoring: ESC 2024 uses CHA₂DS₂-VA (sex category removed); OAC recommended if ≥2, considered if = 1. AHA 2023 retains CHA₂DS₂-VASc (sex retained); OAC recommended if ≥2%/year stroke risk (Class I/A), reasonable if 1–2%/year (Class IIa/A). OAC required in HCM and cardiac amyloidosis regardless of score (ESC: score ≥1 threshold; AHA: treat HCM as score of 3). (sources/AF-ESC-2024, sources/AF-AHA-2023)
DOACs vs. VKAs: DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) preferred over VKAs (Class I/A both guidelines); 50% reduction in intracranial haemorrhage. VKAs mandatory for mechanical valves or moderate-to-severe mitral stenosis (INVICTUS trial). (sources/AF-ESC-2024, sources/AF-AHA-2023)
Device-detected subclinical AF / AHREs:
- SCAF (asymptomatic AF detected by CIED or wearable monitor) is common: 10–50% of CIED populations, 16–30% of ESUS patients on prolonged monitoring. False-positive AHRE rate ~17% (ASSERT) — electrogram review required. SCAF carries 2.4× stroke risk (meta-analysis, n=15,353); dose-dependent with episode duration, risk highest for episodes >24 h. SCAF predicts 5.6–5.9× higher hazard of subsequent clinical AF. (sources/subclinical-af-aha-2019, rating: high)
- ESC 2024: DOAC may be considered (Class IIb/B) in elevated stroke risk + low bleeding risk; ARTESiA trial: apixaban reduced stroke/SE (HR 0.63) but increased major bleeding (HR 1.36). (sources/AF-ESC-2024)
- AHA 2023: OAC reasonable for AHRE ≥24 h + CHA₂DS₂-VASc ≥2 (Class IIa/B-NR); may consider for 5 min–24 h + score ≥3 (Class IIb); not recommended for <5 min (Class III). (sources/AF-AHA-2023)
- See concepts/Subclinical-AF for full prevalence, predictors, stroke risk, and progression data.
pLAAO: Class IIa/B-NR (AHA 2023) for patients with contraindication to long-term OAC — upgraded from IIb. (sources/AF-AHA-2023)
- CLOSURE-AF (NEJM 2026) — landmark negative trial: In 888 elderly AF patients at simultaneously high stroke (mean CHA₂DS₂-VASc 5.2) AND high bleeding risk (mean HAS-BLED 3.0; 85% received DOAC in the medical arm), LAAO failed noninferiority vs physician-directed best medical care (predominantly DOACs): primary composite (stroke/SE/major bleeding/CV death) 16.8 vs 13.3/100 pt-yr; RMST difference −0.36 years (95% CI −0.70 to −0.01); P=0.44 for NI. Stroke was equal (2.6 vs 2.7/100 pt-yr); major bleeding was higher with LAAO (7.4 vs 6.2/100 pt-yr); CV death numerically higher (9.5 vs 7.7/100 pt-yr). The periprocedural + DAPT-driven early bleeding offset the stroke-reduction benefit in this elderly, highest-risk group. This directly challenges the Class IIa recommendation and the rationale for LAAO in the "anticoagulation-unsuitable" high-risk AF population. (sources/laao-closureaf-nejm-2026, rating: very high)
- CHAMPION-AF (NEJM 2026) — positive NI trial in NOAC-eligible AF: In 3,000 patients with AF who were eligible for NOAC therapy (mean CHA₂DS₂-VASc 3.5; mean HAS-BLED 1.3; 68.9% paroxysmal; 47.8% prior ablation), Watchman FLX was noninferior to NOAC for the primary efficacy composite (CV death/stroke/SE: KM 5.7% vs 4.8%; difference 0.9%; P<0.001 for NI; HR 1.20 [95% CI 0.87–1.66]) and superior for non-procedure-related bleeding (KM 10.9% vs 19.0%; HR 0.55 [95% CI 0.45–0.67]; P<0.001). CV death was equal (2.7% vs 2.7%); stroke was numerically higher with LAAO (3.6% vs 2.5%); ischaemic stroke/SE 3.2% vs 2.2%. Net clinical benefit (efficacy + bleeding combined) favoured device (KM 15.1% vs 21.8%; HR 0.66). Post-implant antithrombotic strategy was predominantly NOAC (85%) at discharge — not DAPT — explaining the favourable bleeding profile vs CLOSURE-AF. The key limitation is that the absolute NI margin (4.8 pp) permits up to HR 1.4 for efficacy, and the observed ischaemic stroke excess of ~0.3%/yr may widen at 5-year follow-up. Industry-sponsored (Boston Scientific). (sources/laao-championaf-nejm-2026, rating: very high)

Rate Control

Resting HR target <100–110 bpm (RACE II trial); Class IIa/B-R (AHA 2023); diltiazem/verapamil contraindicated in LVEF <40%. (sources/AF-AHA-2023)

Rhythm Control

Early rhythm control: Implementing rhythm control within 12 months of diagnosis reduces CV death/stroke/HF hospitalisation; Class IIa/B-R (AHA 2023), Class IIa/B (ESC 2024).
EAST-AFNET 4 primary result: HR 0.79 (96% CI 0.66–0.94; P=0.005); CV death HR 0.72; stroke HR 0.65; trial stopped early for efficacy at median 5.1 years; benefit independent of symptom status. (sources/EAST-AFNET4-NEJM-2020, rating: very high; sources/AF-ESC-2024; sources/AF-AHA-2023)

Amiodarone for AF Rhythm Control

Acute pharmacologic cardioversion efficacy: 35–65% (lower than electrical cardioversion 70–90%). Suitable for patients who prefer pharmacologic approach or have concomitant ischaemic heart disease (unlike propafenone or flecainide, which require structurally normal hearts). (sources/amiodarone-cvdrug-2020, rating: high)
Long-term rhythm maintenance: Pooled AFFIRM + AF-CHF (n=3307) — freedom from AF 84% at 1 year and 45% at 5 years. Meta-analysis (n=673): amiodarone more effective than placebo or β-blockers at achieving sinus rhythm (21.3 vs 9.2 events/100 patient-years) without increasing long-term mortality. (sources/amiodarone-cvdrug-2020)
Catheter ablation vs. amiodarone in AF + HF: Di Biase 2016 RCT (n=203, persistent AF + HF + implanted device) — 70% catheter ablation vs. 34% amiodarone patients were AF-free at 2 years. Catheter ablation is preferred in this population. (sources/amiodarone-cvdrug-2020)
In HFrEF: Amiodarone is the only safe antiarrhythmic for rhythm control in HFrEF — propafenone, flecainide, and dronedarone are associated with worse outcomes. SCD-HeFT (n=2521): amiodarone showed no mortality benefit vs placebo in HFrEF (LVEF <35%) — it does not replace ICD as primary prevention strategy. (sources/amiodarone-cvdrug-2020, sources/HF-ESC-2021)
See entities/Amiodarone for full pharmacology, dosing, toxicity monitoring, and drug interactions.

Dronedarone for AF Rhythm and Rate Control

Dronedarone is a non-iodinated amiodarone derivative approved for rhythm and rate control in paroxysmal or persistent AF/flutter. It retains amiodarone's multichannel electrophysiological profile without thyroid, pulmonary, or neurological toxicity, at the cost of lower sustained efficacy. (sources/dronedarone-circ-2009, rating: medium)
EURIDIS/ADONIS (rhythm control): n=1237 in sinus rhythm; dronedarone 400 mg BID vs placebo for 12 months. Median time to first AF recurrence 116 vs 53 days; AF recurrence rate 64.1% vs 75.2%; 27% post hoc RRR in hospitalisation and death. (sources/dronedarone-circ-2009)
ERATO (rate control): In permanent AF on background rate-control therapy, dronedarone reduced resting ventricular rate by 11.7 bpm and exercise rate by 24.5 bpm. (sources/dronedarone-circ-2009)
ATHENA (morbidity/mortality): n=4,628 high-risk AF patients; 24.2% RRR in composite CV hospitalisation or all-cause death (HR 0.76); stroke 34% RRR; arrhythmic death HR 0.55. All-cause mortality HR 0.84 (non-significant). (sources/dronedarone-circ-2009)
ANDROMEDA (TERMINATED): Dronedarone was terminated early in NYHA III/IV CHF + LVEF ≤35% due to excess mortality (HR 2.13). Dronedarone is absolutely contraindicated in severe systolic heart failure. In HFrEF, amiodarone remains the only safe antiarrhythmic. (sources/dronedarone-circ-2009)
Permanent AF: Dronedarone should NOT be used for permanent AF (PALLAS trial, 2011 — outside this source — showed doubled CV events in permanent AF + CV risk factors; label now restricted to paroxysmal/persistent only).
See entities/Dronedarone for full pharmacology, drug interactions, and trial details.

Flecainide for AF Rhythm Control

Flecainide (class 1C) is first-line for pharmacological cardioversion and SR maintenance in patients with structurally normal hearts (no CAD, no LV dysfunction, no cardiomyopathy, no Brugada syndrome). Its key mechanism is post-repolarization refractoriness (PRR) via slow Na+ channel unbinding, producing marked tachycardia-dependent atrial ERP prolongation during AF. (sources/flecainide-af-europace-2011, rating: medium)
IV cardioversion: SR restoration in up to 95% within 1h; head-to-head RCT: flecainide 90% > propafenone 72% > amiodarone 64% (P=0.008). (sources/flecainide-af-europace-2011)
Pill-in-the-pocket (oral loading): 75-85% conversion at 6-8h. Criteria: AF <48h, normal QRS, preserved LV function, no SA/AV node dysfunction, no BBB, no structural cardiomyopathy, no Brugada syndrome. First dose must be in a monitored hospital setting. (sources/flecainide-af-europace-2011)
SR maintenance meta-analysis (60 studies): 65% responsive short-term; 49% long-term. Significant reduction in palpitations, tachycardia, and chest pain vs placebo. (sources/flecainide-af-europace-2011)
Class 1C flutter safety rule: Flecainide can convert AF to atrial flutter with 1:1 AV conduction and fast wide-QRS ventricular response. An AV nodal blocking drug must always be co-prescribed. Isthmus ablation eliminates this risk and reliably controls AF symptoms while flecainide is continued. (sources/flecainide-af-europace-2011)
CAST context and current patient selection: CAST (1991) showed increased mortality in post-MI patients; this excess mortality is attributed to proarrhythmia in structural heart disease, not a class-wide effect. Danish registry (n=151,500): no increased AF mortality with flecainide in appropriately selected patients (annualized mortality 2.54/100 person-years vs amiodarone 7.42). Absolute contraindications: CAD, prior MI, LVEF <35%, structural cardiomyopathy, Brugada syndrome. (sources/flecainide-af-europace-2011)
See entities/Flecainide for full pharmacology, dosing, proarrhythmia management, and CPVT use.

Catheter Ablation

ESC 2024: Class I/A as first-line for paroxysmal AF; Class I/B for persistent AF after failed AADs; Class I for HFrEF if tachycardia-induced cardiomyopathy likely. Uninterrupted OAC required peri-procedure. (sources/AF-ESC-2024)
AHA 2023: Class I/A for younger patients with few comorbidities and paroxysmal AF; Class IIa/B-R for broader paroxysmal/persistent AF population; Class I/A in HFrEF with GDMT. (sources/AF-AHA-2023)
AF progression prevention: EARLY-AF (NEJM 2023): cryoablation as first-line reduced PAF→persistent AF progression from 7.4% (AAD arm) to 1.9% (ablation arm). 'AF begets AF' remodelling paradigm supports early ablation to interrupt progression. (sources/ca-af-ehj-2024, rating: high)
Dementia/cognition: Meta-analysis (15,886 ablated vs 42,684 medically managed AF patients): HR 0.60 for incident dementia (95% CI 0.42–0.88; P<0.05) with catheter ablation. Acute post-ablation MRI cerebral lesions are transient; full cognitive recovery within 12 months. (sources/ca-af-ehj-2024)
QOL: CABANA trial (n=2204): significant improvement in QOL at 12 months, sustained over time, irrespective of AF recurrence; applies across RF, cryo, and PFA modalities. (sources/ca-af-ehj-2024)

Surgical Options

Surgical LAA closure during cardiac surgery: Class I/B (ESC 2024) / Class I/A (AHA 2023) as adjunct to OAC; LAAOS III: HR 0.67 for ischaemic stroke/SE. (sources/AF-ESC-2024, sources/AF-AHA-2023)
[2025 ESC VHD] Surgical LAAO during valve surgery (Class I B): Surgical LAAO is now Class I B in patients with AF undergoing any valve surgery to prevent cardioembolic stroke and systemic thromboembolism (LAAOS III data extended to valve surgery population). (sources/vhd-esc-2025, rating: very high)
[2025 ESC VHD] Surgical AF ablation during valve surgery: Class I A for MV surgery; Class IIa A for non-MV valve surgery — in patients with AF suitable for rhythm control strategy, performed by an experienced electrophysiologist/arrhythmia surgeon team. (sources/vhd-esc-2025, rating: very high)
[2025 ESC VHD] AF-driven atrial SMR and secondary TR: AF is the primary driver of atrial secondary MR (annular dilatation without LV dilation) and atrial secondary TR; rhythm control may reduce SMR and TR severity and reverse LA/RA dilatation. See concepts/Secondary-Mitral-Regurgitation, concepts/Tricuspid-Regurgitation. (sources/vhd-esc-2025, rating: very high)
[2025 ESC VHD] DOACs in VHD+AF: DOACs preferred for AF with AS, AR, or MR (Class I A); DOACs contraindicated (Class III B) if rheumatic MS with MVA ≤2.0 cm² — VKA mandatory in this group. (sources/vhd-esc-2025, rating: very high)

Special Populations

AF in Heart Failure

AF is present in ~25–50% of HF patients; its proportion increases with age and HF severity. When AF causes HF (tachycardiomyopathy), the clinical course is more favourable than AF developing in pre-existing chronic HF. AF onset in chronic HF is associated with worse prognosis including stroke and increased mortality. (sources/HF-ESC-2021, rating: very high)
Anticoagulation: DOACs preferred over VKAs for all HF + AF except moderate/severe mitral stenosis or mechanical valves (Class I). Long-term OAC should be considered in AF patients with CHA2DS2-VASc ≥1 (men) or ≥2 (women) (Class IIa). LA appendage closure may be considered if OAC is contraindicated (Class IIb). (sources/HF-ESC-2021)
Rate control: Lenient rate control (resting HR <110 bpm) is an acceptable initial approach. Beta-blockers are first-line (Class IIa). Digoxin/digitoxin may be added if rate remains high or beta-blockers are not tolerated (Class IIa). Amiodarone i.v. for NYHA IV/haemodynamic instability. AV node ablation Class IIb if medical rate control fails. (sources/HF-ESC-2021)
Rhythm control: Electrical cardioversion is Class I in haemodynamically unstable patients. Amiodarone is the only safe antiarrhythmic drug in HFrEF — propafenone, flecainide, and dronedarone associated with worse outcomes. Antiarrhythmic drug-based rhythm control vs. rate control failed to show benefit in multiple trials in HF. EAST-AFNET 4 (28.6% HF): early rhythm control reduced CV death/stroke/HF hospitalisation/ACS — but catheter ablation was used in only 19.4% of the rhythm control arm. (sources/HF-ESC-2021, sources/EAST-AFNET4-NEJM-2020)
Catheter ablation in HFrEF: CASTLE-AF compared LA catheter ablation vs. medical therapy in 363 patients with persistent/paroxysmal AF + LVEF <35% + implanted device (ICD/CRT-D). Primary endpoint (all-cause death or HF hospitalisation): 28.5% vs. 44.6% (HR 0.62; 95% CI 0.43–0.87; P=0.007). CV death, all-cause death, and HF hospitalisation individually reduced by ablation. However: highly selected population (363 of 3013 screened), not blinded, crossovers between arms, and low event counts. Catheter ablation is recommended (Class IIa) when paroxysmal/persistent AF is clearly associated with worsening HF persisting despite medical therapy. (sources/HF-ESC-2021)

AF in Cancer (Cardio-Oncology)

AF occurs in 2–16% of patients during active cancer therapy; risk depends on cancer type, stage, and treatment. Post-lung surgery incidence is highest (6–32%). All cancer types are associated with higher AF risk than controls. (sources/Cardio-Oncology-ESC-2022, rating: very high)
The cancer–AF relationship is bidirectional: cancer patients have higher AF prevalence, and AF patients have higher cancer incidence — driven by shared risk factors (advanced age, inflammation, metabolic disorders). A study of >15,000 patients confirmed higher prevalent AF in cancer vs. non-cancer controls. (sources/arrhythmia-cardio-oncology-aha-2021, rating: very high)
Cancer-associated AF carries 2× higher stroke/thromboembolism and 6× higher HF risk vs. AF alone. (sources/Cardio-Oncology-ESC-2022)
CHA2DS2-VASc likely underestimates thromboembolic risk in cancer: score = 0 in cancer may not be truly low-risk. Danish registry data: cancer patients with CHA2DS2-VASc 0–1 had higher 2-year stroke risk than non-cancer counterparts. HAS-BLED is also unreliable in cancer — it does not account for thrombocytopenia or intracranial metastases; cancer-specific risk algorithms are urgently needed. (sources/Cardio-Oncology-ESC-2022, sources/arrhythmia-cardio-oncology-aha-2021)
Anticoagulation in cancer + AF (TBIP algorithm):
- T (Thrombotic risk): CHA2DS2-VASc + cancer-type/stage modifiers. OAC recommended for ≥2 (men) or ≥3 (women) [Class I/C]; considered for score 1 (men) or 2 (women) [Class IIa/C]; may consider even for score 0 (men) or 1 (women) after bleeding assessment [Class IIb/C].
- B (Bleeding risk): Thrombocytopaenia; GI/GU malignancy; intracranial lesions; severe renal dysfunction (eGFR <30); HAS-BLED score.
- I (drug–drug Interactions): P-glycoprotein and CYP3A4 interactions with anticancer agents.
- P (Patient preferences and drug availability).
- Very high bleeding risk (platelets <25,000/µL; active/recent major bleeding; intracranial lesions) → no anticoagulation; reassess regularly.
NOAC preferred over LMWH and VKA (Class IIa/B). LMWH preferred over NOACs in: unoperated GI/GU cancer; severe renal dysfunction (CrCl <15 mL/min); platelet count <50,000; major drug interactions. ARISTOTLE subgroup (n=1,236 cancer patients) confirmed apixaban superior to warfarin for stroke/systemic embolism; ENGAGE AF-TIMI 48 showed similar findings for edoxaban. (sources/arrhythmia-cardio-oncology-aha-2021, rating: very high)
Rate control: Beta-blockers are preferred in cancer patients (especially if CTRCD risk). Diltiazem and verapamil should be avoided where possible (drug interactions + negative inotropy). Lenient rate control (HR <110 bpm) is an acceptable initial target. (sources/Cardio-Oncology-ESC-2022)
Rhythm control: Drugs for rhythm control may prolong QTc and interact with anticancer agents. AF ablation should be considered in selected patients (HF/LVD + uncontrolled symptoms), taking cancer status and prognosis into account (MDT approach).
LAA occlusion: Class IIb/C for cancer + AF + contraindication to long-term OAC + life expectancy >1 year. (sources/Cardio-Oncology-ESC-2022)
Post-operative AF in cancer surgery: Associated with 4–5× AF recurrence risk over 5 years and comparable long-term thromboembolic risk to non-surgical AF — anticoagulation should be considered in at-risk patients. (sources/Cardio-Oncology-ESC-2022)
Antiplatelet therapy is NOT recommended for stroke/thromboembolism prevention in cancer + AF (Class III). (sources/Cardio-Oncology-ESC-2022)
BTK inhibitor-associated AF: Ibrutinib (first-generation) is a major cause of AF in haematological malignancy patients. Meta-analysis of 8 RCTs (n=2,580) demonstrated relative risk 4.69 (95% CI 2.17–7.64, P<0.001) for AF; incidence 3.5–16% across studies. Mechanism: BTK/Tec kinase/PI3K inhibition + enhanced sarcoplasmic reticulum Ca²⁺ automaticity. Acalabrutinib (AF 4.1%) and zanubrutinib (AF 2%) have lower AF rates due to higher BTK selectivity. (sources/arrhythmia-cardio-oncology-aha-2021, rating: very high; sources/Cardio-Oncology-ESC-2022)
Opportunistic AF screening (pulse-taking or ECG rhythm strip) is recommended at every clinical visit during BTK inhibitor therapy (Class I/C). TTE in all patients who develop AF during BTK therapy (Class I/C). Ibrutinib should be temporarily interrupted for DAPT and 3–7 days before invasive procedures (bleeding diathesis). (sources/Cardio-Oncology-ESC-2022, rating: very high)

Perioperative AF After Noncardiac Surgery

New-onset POAF: Incidence 0.4–40% after NCS depending on procedure and patient risk; associated with HR 2.00 for 30-day stroke in the NSQIP registry — comparable to the stroke risk of known preoperative AF. (sources/periop-aha-2024, rating: very high)
39% AF recurrence at 5 years after new-onset POAF — distinguishing POAF from transient, perioperative-stress-induced arrhythmia vs unmasked paroxysmal AF is clinically important. (sources/periop-aha-2024, rating: very high)
Acute rate/rhythm control: Follow standard AF management; beta-blockers or calcium channel blockers first-line for rate control; cardioversion for haemodynamic instability. (sources/periop-aha-2024, rating: very high)
Anticoagulation (COR 2a): Initiate anticoagulation for POAF persisting beyond 24–48 h; decisions must balance postoperative bleeding risk vs stroke risk; individualized using CHA₂DS₂-VASc score. (sources/periop-aha-2024, rating: very high)
Outpatient follow-up (COR 2a): All patients with new-onset POAF should have structured outpatient cardiology follow-up — Danish registry data showed 48% reduction in thromboembolism with OAC in post-surgical AF. Prolonged ambulatory monitoring may be appropriate if AF recurrence is suspected. (sources/periop-aha-2024, rating: very high)

ACS and AF: Antithrombotic Strategy (Early Post-PCI/ACS Period)

[2025 ACC/AHA ACS Guideline] Triple therapy → dual therapy: In patients with ACS who require oral anticoagulation (most commonly due to AF), aspirin should be discontinued 1–4 weeks post-PCI with continued P2Y12 inhibitor (preferably clopidogrel) + OAC — Class I/B-R. (sources/ACS-AHA-2025, rating: very high)
RCT evidence (RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI, PIONEER AF-PCI): aspirin discontinuation reduces major bleeding without significant increase in all-cause/CV death, stroke, or overall MACE vs triple therapy. (sources/ACS-AHA-2025, rating: very high)
~80% of stent thrombosis events occur within 30 days of PCI. For patients at high stent thrombosis risk, aspirin may be continued up to 30 days before discontinuation. (sources/ACS-AHA-2025, rating: very high)
DOAC preferred over VKA in most ACS + AF patients (except mechanical valves, rheumatic MS with MVA ≤2.0 cm²). (sources/ACS-AHA-2025, rating: very high)
Clopidogrel is preferred as the P2Y12 inhibitor in patients on OAC (prasugrel and ticagrelor trials excluded OAC patients; more potent agents theoretically increase bleeding). (sources/ACS-AHA-2025, rating: very high)
P2Y12 inhibitor therapy should be continued for at least 12 months post-PCI after aspirin discontinuation (can be discontinued earlier in patients with multiple bleeding risk factors). (sources/ACS-AHA-2025, rating: very high)
See concepts/DAPT-Strategies for complete DAPT management framework. See entities/Acute-Coronary-Syndrome for full ACS management.

Stable CAD and AF: Long-Term Antithrombotic Strategy (Beyond 6–12 Months)

In patients with AF who have stable coronary artery disease (≥6–12 months after the index coronary event or PCI), the question shifts to whether OAC monotherapy is sufficient — eliminating excess bleeding from the antiplatelet while preserving ischemic protection. See concepts/AF-Stable-CAD-Antithrombotic for full evidence synthesis.

AFIRE (2019, rivaroxaban): Rivaroxaban monotherapy noninferior to rivaroxaban + antiplatelet for ischemic events and superior for MACE and bleeding in AF + stable CAD. However, used non-standard rivaroxaban dose (15/10 mg; Japanese-approved) and predominantly low-risk patients. Current 2023 AHA/ACC CCD Guideline: DOAC monotherapy COR 2b/C-LD after 1 year post-PCI in AF + stable CAD. (sources/CCS-AHA-2023, rating: very high)
EPIC-CAD (2024, NEJM; standard-dose edoxaban): 1,040 patients; AF (CHA₂DS₂-VASc ≥2) + stable CAD (PCI ≥6 months, ACS ≥12 months, or medically managed ≥50% stenosis); mean age 72; mean CHA₂DS₂-VASc 4.3; 12-month follow-up:
- Net adverse clinical events (NACE): 6.8% vs 16.2%; HR 0.44 (95% CI 0.30–0.65; P<0.001); NNT = 10.6
- Major ischemic events: 1.6% vs 1.8%; HR 1.23; NS — statistically similar (trial not powered for this)
- Major + CRNM bleeding: 4.7% vs 14.2%; HR 0.34 (95% CI 0.22–0.53)
- Major bleeding: 1.3% vs 4.5%; HR 0.32 (95% CI 0.14–0.73)
- Results consistent whether antiplatelet was aspirin or clopidogrel, and regardless of CAD management strategy
- First RCT to use standard-dose edoxaban and include medically managed (non-revascularized) stable CAD
- Limitations: Open-label; East Asian population only; NACE endpoint biases toward less potent antithrombotic; underpowered for ischemic outcomes. (sources/edoxaban-af-cad-nejm-2024, rating: high)

Anticoagulation After Acute Ischemic Stroke in AF

Early OAC (within 4–14 days) — COR 2a: ELAN trial (n=2,013, open-label RCT) — early OAC initiation (within 48h for minor, 3–7d for moderate, 6–7d for severe strokes) non-inferior to delayed (≥14 days) for recurrent ischaemic stroke, with no increase in symptomatic ICH at 30 days. (sources/ais-aha-2026, rating: very high)
Timing by stroke severity: Minor/moderate AIS: early initiation reasonable; severe AIS (NIHSS >15) with large infarct: delay ≥14 days to minimise hemorrhagic transformation risk; ELAN underrepresented large infarcts and patients with hemorrhagic transformation.
Heparin bridging — COR 3: Harm: Not recommended while awaiting OAC — no benefit, increases intracranial haemorrhage; hold heparin and start OAC directly when appropriate timing is reached. (sources/ais-aha-2026, rating: very high)
DOAC preferred over VKA for most AF-related stroke (except mechanical valves, rheumatic MS with MVA ≤2.0 cm²); DOAC agents: apixaban, dabigatran, edoxaban, rivaroxaban. (sources/AF-AHA-2023, rating: very high)
See entities/Ischemic-Stroke for full AIS acute management, BP targets, and antiplatelet strategies.
See concepts/DAPT-Strategies for antiplatelet management in minor AIS/TIA (DAPT ×21d COR 1A).

Genetics

Early-onset AF yield: In a prospective cohort of 1293 patients with AF diagnosed before age 66 undergoing whole-genome sequencing, 10.1% carried a disease-associated (P/LP) variant in a cardiomyopathy or arrhythmia gene — rising to 16.8% in those diagnosed before age 30. Most pathogenic variants were in cardiomyopathy genes (TTN, MYH7, MYH6, LMNA), not channelopathy genes. Supports a model where early-onset AF often represents the first manifestation of an underlying inherited cardiomyopathy ("atrial myopathy"). (sources/eoaf-jama-2021, rating: high)
Patients with early-onset AF and a disease-associated variant were significantly more likely to have heart failure (27.5% vs ~15%) and reduced ejection fraction (15.3% vs 6.6–7.3%). (sources/eoaf-jama-2021)
Clinical testing thresholds (AHA 2023): EP study reasonable for AF <30 years (24–39% have reentrant SVT); genetic testing reasonable for AF <45 years without obvious risk factors (Class IIb/B-NR; 24% yield in selected series). (sources/AF-AHA-2023)
Atrial myopathy in sarcomeric HCM: MYBPC3 and MYH7 variant–positive HCM patients have significantly more LA fibrosis by electroanatomical voltage mapping than gene-negative HCM controls, despite similar LA pressures — supporting primary genetic atrial myopathy as an AF mechanism independent of hemodynamic loading. This extends the "atrial myopathy" concept beyond pressure-overload to genetically driven substrate. See concepts/Atrial-Myopathy-in-HCM. (sources/MYBPC3-MYH7-JACCEP-2024, rating: medium)
AF before age 40 without SHD — high lifestyle RF burden and genetic yield: In the largest prospective cohort of AF <40 without structural heart disease (n=122; mean age 31.2 years; 83% male), 89% had ≥1 lifestyle risk factor (obesity/overweight 30%; intensive sport 27%; alcohol 22%; drugs 11%) and 25% had hereditary predisposition. Genetic panel testing in 57% yielded P/LP variants in 11.6% (TTN ×4, LMNA ×2, PKP2 ×2, TNNI3 ×1 — cardiomyopathy genes 74%). These findings confirm that even structurally normal very young AF has high modifiable risk factor burden and meaningful genetic yield. (sources/eoaf-riskfactor-ehj-2026, rating: medium)
Stroke in very young AF with CHA₂DS₂-VA = 0: Despite 93% of the cohort having CHA₂DS₂-VA = 0 and no patient being anticoagulated, 5 patients (4.1%) suffered a stroke — 4 at the initial AF presentation. This challenges the assumption that a score of 0 confers negligible stroke risk in very young AF, though the mechanism (LA thrombus vs. paradoxical embolism vs. AF-related low flow) was not characterized. (sources/eoaf-riskfactor-ehj-2026)

Gene Therapy and Biological Therapies (Preclinical)

All studies below are preclinical (animal models); no human AF biological therapy trials have been reported. A systematic review (McRae et al., Heart Rhythm 2019; n=25 studies) found that biological therapies — pooled across gene therapy, miRNA manipulation, and cell therapy — reduced AF inducibility by 85% (OR 0.15; P<0.01), reduced atrial fibrosis by 6.7% (P<0.01), and increased days in sinus rhythm by +6.4 (P<0.01) vs controls. Despite universal preclinical success, no biological therapy has entered clinical trials (see concepts/AF-Biological-Therapy for delivery barriers and translational gaps). (sources/biological-tx-af-hrs-2019, rating: medium; sources/gene-therapy-arrhythmia-2025, rating: high)

IKr modulation (KCNH2 dominant-negative): KCNH2-G628S adenovirus in pigs (Amit 2010; Soucek 2012) — prolonged atrial APD; reduced AF risk RR 0.44; effect lost at 21 days (adenoviral washout). Validated by 2 independent labs. (sources/gene-therapy-arrhythmia-2025, sources/biological-tx-af-hrs-2019)
IK1 suppression: Dominant-negative Kir2.1AAA prolonged atrial ERP (131→174 ms) and reduced AF episodes (2.7→0.4/min) in porcine models without ventricular effects (Bikou 2011). (sources/gene-therapy-arrhythmia-2025)
Gap junction restoration (Cx43/Cx40): Adenoviral GJA1/GJA5 overexpression in pigs (Igarashi 2012; Bikou 2011) — preserved atrial conduction velocity (41 vs 27 cm/s), reduced AF inducibility >80%, +6.6 days sinus rhythm; 2 independent labs. (sources/gene-therapy-arrhythmia-2025, sources/biological-tx-af-hrs-2019)
Anti-fibrosis — anti-miR-21 (most replicated): miR-21 promotes atrial fibrosis via PTEN/Sprouty suppression; anti-miR-21 reduced atrial scar by 5–10% in 4 independent labs (Cardin/Adam/He/Huang; rat/mouse/rabbit models). (sources/biological-tx-af-hrs-2019)
Anti-fibrosis — TGF-β blockade: Dominant-negative TGF-β1 receptor plasmid in dogs (Kunamalla 2016) — fibrosis −8.7%, preserved conduction velocity, shortened AF duration. ACE2 overexpression (adenovirus epicardial; Fan/Zhou ×2 in dogs) — fibrosis −6–9%, reduced AF inducibility. (sources/gene-therapy-arrhythmia-2025, sources/biological-tx-af-hrs-2019)
Autonomic modulation: Gαi C-terminal peptide plasmid (Aistrup 2011) — disrupts IKACh activation by muscarinic receptors; dogs; only study with dose-response relationship. miR-206 suppression (Zhang 2015; lentivirus; dogs) — modulates sympathetic nerve remodelling via SOD1. (sources/gene-therapy-arrhythmia-2025, sources/biological-tx-af-hrs-2019)
Anti-apoptosis: siRNA caspase-3 knockdown (Trappe 2013; plasmid; pigs) — reduced cardiomyocyte apoptosis and delayed sustained AF progression; +4.3 days sinus rhythm. (sources/gene-therapy-arrhythmia-2025, sources/biological-tx-af-hrs-2019)
SERCA2a overexpression (AAV9): Rabbit burst-pacing model; normalises SR Ca²⁺ cycling; reduces triggered activity from Ca²⁺ sparks/NCX. (sources/biological-tx-af-hrs-2019)
Key translational barrier: All 25 studies delivered therapy before AF onset (clinically unrealistic); all used invasive local delivery; 80% used transient adenovirus/plasmid (3–4-day expression); group sizes n=5–16; zero published failures (publication bias). AAV-based durable delivery + multi-target strategies are the path forward. (sources/biological-tx-af-hrs-2019)

Atrial Cardiomyopathy as the Substrate for AF

AtCM Framework — AF as a Manifestation, Not the Cause

The 2025 ESC/HFA consensus statement reframes AF: rather than treating AF as the primary driver of stroke and HF, atrial cardiomyopathy (AtCM) is the underlying substrate, with AF as one of its manifestations or consequences. In many patients, stroke and dementia risk are more strongly driven by atrial structural disease (LA size, LASr) than by AF episodes per se. (sources/atrial-cmp-esc-2025, rating: high)
Subclinical AF >6 min is detected in only 15% of patients during the month before an embolic event (pacemaker data) — confirming that AF is often an intermittent marker of underlying atrial disease, not the proximate cause. (sources/atrial-cmp-esc-2025, rating: high)
LASr is more closely associated with stroke and dementia risk than AF; mechanical atrial dysfunction is an independent and better predictor than AF for adverse outcomes in HFpEF. (sources/atrial-cmp-esc-2025, rating: high)

AtCM Diagnostic Criteria

AtCM diagnosis = electrical atrial dysfunction (P-wave score ≥1) + one of: mechanical atrial dysfunction (LASr <23% or LAVi >40 ml/m²), atrial enlargement, or excessive atrial fibrosis (CMR-LGE ≥10–15%)
P-wave score 3 (advanced IAB + paroxysmal AF) and score 4 (persistent AF) represent established AtCM/atrial failure — standard AF management applies.
See concepts/Atrial-Cardiomyopathy for the full diagnostic framework and imaging cut-offs.

ARCADIA Trial — Anticoagulation in AtCM-Defined Cryptogenic Stroke

ARCADIA trial used BNP >250 pg/mL or PTF-V1 >40 mm/ms as markers of AtCM to define a subgroup of cryptogenic stroke patients who might benefit from anticoagulation (apixaban vs. aspirin for secondary stroke prevention). The trial was stopped early for futility — no benefit of apixaban over aspirin in this AtCM-defined subgroup. (sources/atrial-cmp-esc-2025, rating: high)
This raises the question of whether the AtCM markers used were inadequate to identify the target population, or whether anticoagulation without documented AF truly lacks efficacy in AtCM. Dedicated RCTs in AtCM are needed.

Contradictions / Open Questions

LAAO in high-risk AF — AHA Class IIa vs CLOSURE-AF (NEJM 2026): The AHA 2023 guideline gives LAAO a Class IIa/B-NR recommendation for AF patients with contraindication to long-term OAC. CLOSURE-AF (n=888; elderly; mean CHA₂DS₂-VASc 5.2, HAS-BLED 3.0; 85% DOAC in medical arm) directly challenges this: LAAO failed noninferiority vs DOACs (P=0.44 for NI; RMST difference −0.36 years; device group numerically worse on all components). Stroke was equal, but major bleeding was higher with LAAO (7.4 vs 6.2/100 pt-yr) and CV death was numerically higher (9.5 vs 7.7/100 pt-yr). The fundamental problem is that periprocedural risk + DAPT-driven early bleeding negates any later stroke prevention benefit in the oldest, sickest patients — the very population LAAO is supposed to help. AHA guideline downgrade is anticipated. (sources/laao-closureaf-nejm-2026, rating: very high)
CHAMPION-AF vs CLOSURE-AF — same intervention, opposite NI conclusions (NEJM 2026): Both trials compared LAAO vs NOAC and were published in the same issue of NEJM 2026, yet reached opposite conclusions on noninferiority. CHAMPION-AF (n=3,000; mean CHA₂DS₂-VASc 3.5; HAS-BLED 1.3; NOAC-eligible; Watchman FLX + 85% NOAC post-implant): NI demonstrated for efficacy (P<0.001) + superiority for bleeding (HR 0.55; P<0.001). CLOSURE-AF (n=888; mean CHA₂DS₂-VASc 5.2; HAS-BLED 3.0; anticoagulation-unsuitable; multiple devices + predominantly DAPT post-implant): NI failed (P=0.44 for NI; device numerically worse). The divergence is mechanistically coherent: (1) risk profile — higher-risk elderly patients accumulate more periprocedural harm relative to baseline thromboembolic risk; (2) post-implant antithrombotic strategy — NOAC post-implant (CHAMPION-AF) eliminates the DAPT-driven early bleeding that negated LAAO benefit in CLOSURE-AF; (3) NI margin structure — absolute (CHAMPION-AF) vs relative (CLOSURE-AF), affecting apparent permissiveness at low event rates. Taken together, these two trials suggest LAAO may benefit lower-to-moderate risk NOAC-eligible patients (CHAMPION-AF population), but is harmful or neutral in the highest-risk anticoagulation-unsuitable elderly AF population (CLOSURE-AF population) — the exact group for whom it was previously most advocated. (sources/laao-championaf-nejm-2026, sources/laao-closureaf-nejm-2026, rating: very high)
OPTION vs CLOSURE-AF/CHAMPION-AF — three-trial LAAO NI landscape: OPTION (NEJM 2025) demonstrated NI of LAAO vs OAC after AF ablation. CHAMPION-AF demonstrated NI + bleeding superiority in NOAC-eligible moderate-risk patients. CLOSURE-AF failed NI in the highest-risk anticoagulation-unsuitable population. Patient risk stratification (CHA₂DS₂-VASc + HAS-BLED) and post-implant antithrombotic protocol are the key determinants of outcome. LAAO may be appropriate in lower-to-moderate-risk patients on post-implant NOAC; it is not a blanket anticoagulation substitute for the highest-risk group. (sources/laao-closureaf-nejm-2026, sources/laao-championaf-nejm-2026, rating: very high)
AtCM vs. AF-first paradigm (NEW — 2025): The ESC/HFA 2025 AtCM consensus positions AF as a late manifestation of underlying atrial cardiomyopathy, not the primary driver of stroke/HF. This directly challenges AF-centric risk stratification frameworks (CHA₂DS₂-VA/VASc, AF staging) where AF is the primary diagnosis. If atrial structural disease predicts stroke independently of AF, current OAC thresholds (tied to AF detection and duration) may systematically miss patients most at risk. (sources/atrial-cmp-esc-2025, rating: high; sources/AF-ESC-2024, rating: very high)
ARCADIA futility vs. anticoagulation expectation: ARCADIA showed no benefit of apixaban over aspirin in AtCM-defined cryptogenic stroke — counter to the biological hypothesis that AtCM is a thrombogenic substrate. Marker adequacy (BNP thresholds, PTF-V1) and patient selection remain unresolved. (sources/atrial-cmp-esc-2025, rating: high)
CABANA trial showed no significant mortality benefit of catheter ablation vs. drug therapy in all-comers; CASTLE-AF showed benefit in HFrEF — patient selection is critical. (sources/AF-ESC-2024, sources/AF-AHA-2023)
Optimal duration of device-detected subclinical AF warranting OAC remains undefined; ARTESiA and NOAH trials gave discordant results. (sources/AF-ESC-2024)
Whether OAC can be safely stopped after successful catheter ablation in high-risk patients is unresolved; current guidelines recommend continuing OAC based on stroke risk regardless of rhythm. (sources/AF-ESC-2024, sources/AF-AHA-2023)
ESC vs. AHA sex category in risk score: ESC 2024 uses CHA₂DS₂-VA (sex removed), while AHA 2023 retains CHA₂DS₂-VASc (sex retained). Clinically relevant discrepancy for women with only sex as a risk factor (score = 1 by AHA; 0 by ESC). (sources/AF-AHA-2023, sources/AF-ESC-2024)
Device-detected AHRE anticoagulation thresholds differ by guideline: AHA 2023 uses explicit duration-based thresholds (≥24 h + score ≥2 = Class IIa; 5 min–24 h + score ≥3 = Class IIb; <5 min = no OAC); ESC 2024 applies a single Class IIb/B recommendation without strict duration cutoffs. (sources/AF-AHA-2023, sources/AF-ESC-2024)
ESC 2021 vs. ESC 2024 anticoagulation threshold in HF+AF: ESC 2021 uses CHA2DS2-VASc (score ≥1 men, ≥2 women = Class IIa for OAC). ESC 2024 adopts CHA2DS2-VA (sex category removed; OAC if ≥2, consider if =1). Clinically discrepant for women with sex as their only risk factor. (sources/HF-ESC-2021, sources/AF-ESC-2024)
CHA2DS2-VASc vs. cancer: This guideline (ESC 2022 Cardio-Oncology) uses CHA2DS2-VASc (the older score) and notes it underestimates thromboembolic risk in cancer. The newer ESC 2024 AF guidelines use CHA2DS2-VA. In cancer patients, both scores should be considered lower-bound estimates. (sources/Cardio-Oncology-ESC-2022, sources/AF-ESC-2024)

Connections

Related to concepts/Atrial-Cardiomyopathy
Related to concepts/Atrial-Failure
Related to entities/Amiodarone
Related to entities/Dronedarone
Related to entities/Flecainide
Related to entities/Hypertension
Related to entities/MASLD
Related to entities/Obesity
Related to entities/Obstructive-Sleep-Apnea
Related to entities/Ischemic-Stroke
Related to entities/Atrial-Flutter
Related to entities/HCM
Related to entities/TTN
Related to entities/LMNA
Related to entities/KCNH2
Related to concepts/Drug-Induced-Arrhythmia
Related to concepts/OSA-Arrhythmogenic-Substrate
Related to concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis
Related to concepts/Visceral-Adiposity
Related to concepts/Secondary-Mitral-Regurgitation
Related to concepts/Tricuspid-Regurgitation
Related to concepts/Mitral-Stenosis
Related to concepts/Valvular-Heart-Disease
Related to concepts/AF-CARE
Related to concepts/AF-Staging
Related to concepts/CHA2DS2-VA
Related to concepts/Catheter-Ablation-AF
Related to concepts/AF-Biological-Therapy
Related to concepts/Gene-Silencing-Therapy
Related to concepts/AAV-Gene-Delivery
Related to concepts/Ion-Channel-Mutations
Related to concepts/Cardiac-Action-Potential
Related to concepts/Electrical-Remodeling
Related to concepts/Early-Onset-Atrial-Fibrillation
Related to concepts/Genetic-Testing-in-AF
Related to concepts/Pulsed-Field-Ablation
Related to concepts/Atrial-Myopathy-in-HCM
Related to concepts/Cardio-Oncology
Related to concepts/Cancer-Therapy-Related-CV-Toxicity
Related to concepts/Cancer-Associated-Arrhythmia
Related to concepts/Perioperative-Cardiovascular-Assessment
Related to concepts/Heart-Healthy-Dietary-Patterns
Related to concepts/Subclinical-AF
Related to concepts/DAPT-Strategies
Related to concepts/AF-Stable-CAD-Antithrombotic
Related to sources/membrane-potential-physrev-2021
Related to sources/EAST-AFNET4-NEJM-2020
Related to sources/HF-ESC-2021
Related to sources/Cardio-Oncology-ESC-2022
Related to sources/arrhythmia-cardio-oncology-aha-2021
Related to sources/periop-aha-2024
Related to sources/epi-adipose-arrhythmia-jacc-2021
Related to sources/dronedarone-circ-2009
Related to sources/flecainide-af-europace-2011
Related to sources/subclinical-af-aha-2019